Private Equity Investment in Clinical Trial Sites Raises Potential Antitrust, CPOM Concerns

Private equity’s growing interest in clinical trial sites and services raises questions about how increased consolidation will impact the cost and sustainability of pharmaceutical research and development (R&D), and this trend could implicate both antitrust law and state Corporate Practice of Medicine (CPOM) doctrines, sources told The Capitol Forum. “Clinical trial sites are a critical […]

CRH/Arcosa: Building Materials Supplier Tie Up Pulled and Refiled Pre-merger Paperwork in Early August

CRH (CRH) refiled their pre-merger notification form with the FTC and DOJ in early August, a spokesperson for CRH said, adding that the move is not expected to affect the parties’ plan to close...

Aug 27, 2026 Read Now >

Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and ‘Fudged’ Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation

An ongoing Capitol Forum investigation of VITAS Healthcare, a subsidiary of Chemed (CHE) and the largest hospice provider in the nation, has found that the company is enrolling patients into hospice...

Aug 26, 2026 Read Now >

Hanwha Group/Austal USA: Bid for U.S. Navy Shipbuilder Could Face Heavy Seas, Including Whether Trump’s Anger at South Korea Will Complicate Deal

South Korean shipbuilder Hanwha Group’s (KRX: 000880) $1.2 billion bid earlier this month to acquire the U.S operations of Australia’s Austal Limited (ASX: ASB) could be complicated by...

Aug 25, 2026 Read Now >

Private Equity Investment in Clinical Trial Sites Raises Potential Antitrust, CPOM Concerns

RELATED ARTICLES | Corporate investigations

CRH/Arcosa: Building Materials Supplier Tie Up Pulled and Refiled Pre-merger Paperwork in Early August

Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and ‘Fudged’ Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation

Hanwha Group/Austal USA: Bid for U.S. Navy Shipbuilder Could Face Heavy Seas, Including Whether Trump’s Anger at South Korea Will Complicate Deal

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.